Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer

X Ouyang, WJ Jessen, H Al-Ahmadie, AM Serio, Y Lin… - Cancer research, 2008 - AACR
X Ouyang, WJ Jessen, H Al-Ahmadie, AM Serio, Y Lin, WJ Shih, VE Reuter, PT Scardino…
Cancer research, 2008AACR
To identify biomarkers that discriminate the aggressive forms of prostate cancer, we
performed gene expression profiling of prostate tumors using a genetically engineered
mouse model that recapitulates the stages of human prostate cancer, namely Nkx3. 1; Pten
mutant mice. We observed a significant deregulation of the epidermal growth factor and
mitogen-activated protein kinase (MAPK) signaling pathways, as well as their major
downstream effectors—the activator protein-1 transcription factors c-Fos and c-Jun. Forced …
Abstract
To identify biomarkers that discriminate the aggressive forms of prostate cancer, we performed gene expression profiling of prostate tumors using a genetically engineered mouse model that recapitulates the stages of human prostate cancer, namely Nkx3.1; Pten mutant mice. We observed a significant deregulation of the epidermal growth factor and mitogen-activated protein kinase (MAPK) signaling pathways, as well as their major downstream effectors—the activator protein-1 transcription factors c-Fos and c-Jun. Forced expression of c-Fos and c-Jun in prostate cancer cells promotes tumorigenicity and results in activation of extracellular signal-regulated kinase (Erk) MAPK signaling. In human prostate cancer, up-regulation of c-Fos and c-Jun proteins occurs in advanced disease and is correlated with Erk MAPK pathway activation, whereas high levels of c-Jun expression are associated with disease recurrence. Our analyses reveal a hitherto unappreciated role for AP-1 transcription factors in prostate cancer progression and identify c-Jun as a marker of high-risk prostate cancer. This study provides a striking example of how accurate mouse models can provide insights on molecular processes involved in progression and recurrence of human cancer. [Cancer Res 2008;68(7):2132–44]
AACR